Summary Heterozygous mutation of IDH1 in cancers modifies IDH1 enzymatic activity, reprogramming metabolite flux and markedly elevating 2-hydroxyglutarate (2-HG). Here, we found that 2-HG depletion did not inhibit growth of several IDH1 mutant solid cancer types. To identify other metabolic therapeutic targets, we systematically profiled metabolites in endogenous IDH1 mutant cancer cells after mutant IDH1 inhibition and discovered a profound vulnerability to depletion of the coenzyme NAD+. Mutant IDH1 lowered NAD+ levels by downregulating the NAD+ salvage pathway enzyme nicotinate phosphoribosyltransferase (Naprt1), sensitizing to NAD+ depletion via concomitant nicotinamide phosphoribosyltransferase (NAMPT) inhibition. NAD+ depletion activated the intracellular energy sensor AMPK, triggered autophagy and resulted in cytotoxicity. Thus, we identify NAD+ depletion as a metabolic susceptibility of IDH1 mutant cancers.
Studies have shown that DNA (cytosine-5-)-methyltransferase 1 (DNMT1) is the principal enzyme responsible for maintaining CpG methylation and is required for embryonic development and survival of somatic cells in mice. The role of DNMT1 in human cancer cells, however, remains highly controversial. Using homologous recombination, here we have generated a DNMT1 conditional allele in the human colorectal carcinoma cell line HCT116 in which several exons encoding the catalytic domain are flanked by loxP sites. Cre recombinase-mediated disruption of this allele results in hemimethylation of approximately 20% of CpG-CpG dyads in the genome, coupled with activation of the G2/M checkpoint, leading to arrest in the G2 phase of the cell cycle. Although cells gradually escape from this arrest, they show severe mitotic defects and undergo cell death either during mitosis or after arresting in a tetraploid G1 state. Our results thus show that DNMT1 is required for faithfully maintaining DNA methylation patterns in human cancer cells and is essential for their proliferation and survival.
Increased methylation of CpG islands and silencing of affected target genes is frequently found in human cancer; however, in vivo the question of causality has only been addressed by loss-of-function studies. To directly evaluate the role and mechanism of de novo methylation in tumor development, we overexpressed the de novo DNA methyltransferases Dnmt3a1 and Dnmt3b1 in Apc Min/+ mice. We found that Dnmt3b1 enhanced the number of colon tumors in Apc Min/+ mice approximately twofold and increased the average size of colonic microadenomas, whereas Dnmt3a1 had no effect. The overexpression of Dnmt3b1 caused loss of imprinting and increased expression of Igf2 as well as methylation and transcriptional silencing of the tumor suppressor genes Sfrp2, Sfrp4, and Sfrp5. Importantly, we found that Dnmt3b1 but not Dnmt3a1 efficiently methylates the same set of genes in tumors and in nontumor tissues, demonstrating that de novo methyltransferases can initiate methylation and silencing of specific genes in phenotypically normal cells. This suggests that DNA methylation patterns in cancer are the result of specific targeting of at least some tumor suppressor genes rather than of random, stochastic methylation followed by clonal selection due to a proliferative advantage caused by tumor suppressor gene silencing.[Keywords: DNA methylation; epigenetics; cancer; Dnmt3b; APC] Supplemental material is available at http://www.genesdev.org. Received July 17, 2007; revised version accepted October 11, 2007. Cancer cells show widespread epigenetic changes when compared with their normal parental tissue, including changes in DNA methylation and chromatin modification (Jones and Baylin 2007). The first epigenetic abnormality reported for human cancer was a global decrease in genomic cytosine methylation (Feinberg and Vogelstein 1983), most often seen in repetitive sequences and intergenic regions. It promotes genetic instability, increases the mobility of transposable elements (Walsh et al. 1998), and induces tumorigenesis in several different mouse models Gaudet et al. 2003;Yamada et al. 2005;Jones and Baylin 2007). Thus, hypomethylation predisposes to genetic damage and increases the risk of tumor development. Conversely, in some tissues global hypomethylation can also inhibit tumor outgrowth (Laird et al. 1995).In addition to global hypomethylation, it was also found that the cancer cell genome frequently contains regions with increased cytosine methylation (Baylin et al. 1986). This regional hypermethylation often affects CpG islands that are associated with promoter regions (Herman and Baylin 2003;Feinberg and Tycko 2004;Jones and Baylin 2007). Regional hypermethylation attracted attention when it was linked to transcriptional silencing of the RB tumor suppressor gene in patients with retinoblastoma tumors (Greger et al. 1989(Greger et al. , 1994. Multiple follow-up studies revealed that in cancer many tumor-relevant genes, in particular tumor suppressor genes, are transcriptionally silenced by hypermethylation. Aberrant DNA met...
Background: Mutant-selective IDH1 inhibitors are potential cancer therapeutics, but the mechanistic basis for their selectivity is not yet well understood. Results: Inhibitor binding modes and kinetic mechanisms were characterized. Conclusion:The inhibitors selectively inhibit mutant IDH1 by interacting with a magnesium-binding residue. Significance: Targeting metal-binding residues with drug-like small molecules is a feasible strategy for IDH1 inhibition.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.